Pharming announces extension of their license agreement for the commercialisation of Ruconest®
(Thomson Reuters ONE) -
Leiden, The Netherlands, August 15, 2011. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that they have agreed an
extension of their existing agreement with Swedish Orphan Biovitrum (STO: SOBI)
to include new territories in the Balkans, North Africa and the Middle East for
the commercialization of Ruconest® (recombinant human C1 inhibitor) for the
treatment of acute angioedema attacks in patients with Hereditary Angioedema
(HAE).
In addition, SOBI has placed a significant additional order for vials of
Ruconest®. The shipment forms part of SOBI's preparation for the continued roll-
out and intensified marketing of Ruconest® across Europe. SOBI will over a
period of 1 year pay ?1.5 million to Pharming for these additional shipments
under this order. Under the terms of the distribution partnership, SOBI buys
finished product from Pharming for a transfer price that includes a sales
related tiered royalty component.
Sijmen de Vries, CEO of Pharming, said "We are delighted to expand our current
commercialization deal with SOBI. This is another significant step towards
making Ruconest more widely available. With this extension, patients in all EC
territories, the Balkans, North Africa and the Middle East will soon be able to
benefit from the efficacy and safety that Ruconest offers as the only
recombinant enzyme replacement therapy for HAE".
About Ruconest (Rhucin) and Hereditary Angioedema
Ruconest® / Rhucin® (INN conestat alfa) is a recombinant version of the human
protein C1 inhibitor (C1INH). Rhucin is produced through Pharming's proprietary
technology in milk of transgenic rabbits and in Europe is approved under the
name Ruconest® for treatment of acute angioedema attacks in patients with HAE.
Rhucin has been granted orphan drug designation in the U.S. for the treatment of
acute attacks of HAE, a genetic disorder in which the patient is deficient in or
lacks a functional plasma protein C1 inhibitor, resulting in unpredictable and
debilitating episodes of intense swelling of the extremities, face, trunk,
genitals, abdomen and upper airway. The frequency and severity of HAE attacks
vary and are most serious when they involve laryngeal edema, which can close the
upper airway and cause death by asphyxiation. According to the U.S. Hereditary
Angioedema Association, epidemiological estimates for HAE range from one in
10,000 to one in 50,000 individuals.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. Ruconest(®) (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (STO:
SOBI). The product is also under development for follow-on indications, i.e.
antibody-mediated rejection (AMR) and delayed graft function (DGF) following
kidney transplantation. The advanced technologies of the Company include
innovative platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. Additional
information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Pharming
Karl Keegan, CFO,
Rienk Pijpstra, CMO
T: +31 (0)71 52 47 400
Financial Dynamics
Julia Phillips/ John Dineen
Press release (PDF):
http://hugin.info/132866/R/1538336/469852.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1538336]
Unternehmensinformation / Kurzprofil:
Datum: 15.08.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 57234
Anzahl Zeichen: 4963
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming announces extension of their license agreement for the commercialisation of Ruconest®"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
